, Sept. 21
/PRNewswire/ -- Cardiac Science Corporation
(Nasdaq: CSCX), a global leader in automated external defibrillator (AED
) and diagnostic cardiac monitoring devices, today announced the launch of a Microvolt T-Wave Alternans (MTWA) module that integrates with its industry-leading Quinton Q-Stress cardiac stress systems
"Physicians that have Q-Stress systems can add the MTWA module to their existing Q-Stress systems, or order it as an option with new systems," said Tony Titus, Cardiac Science vice president of marketing. "The MTWA test is a clinically proven test for assessing the risk of sudden cardiac arrest and it can be performed during a standard stress test session. It is the only test of its kind that Medicare will reimburse."
Cardiac Science teamed with Tewksbury, MA-based Cambridge Heart (OTC Bulletin Board: CAMH), a developer of noninvasive diagnostic tests for cardiac disease, to create the MTWA module that has been integrated into the Q-Stress systems.
"We are pleased to have reached this key milestone, and look forward to working with Cardiac Science to support the sales and marketing phase of our partnership," said Ali Haghighi-Mood, Cambridge Heart's President and CEO. "The launch of the MTWA module for the Q-Stress system marks an important step in making our technology accessible to a much broader segment of physicians and patients."
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
For updates and information on worldwide defibrillation and cardiac monitoring, find us on the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, Facebook at http://budurl.com/CSonFB, and YouTube at http://budurl.com/CSonYT.
Information concerning reimbursement by Medicare and/or other third party sources may not be accurate, and is subject to change without notice as a result of changing laws and policies. The information is not intended to increase or maximize reimbursement from any third party payers, and is not intended as a guarantee or promise of reimbursement or payment. Physicians and other providers are responsible for understanding and complying with Medicare or other third party payer policies and payment requirements, including credentials, professional training, and certification. The physician or other provider is also responsible for proper documentation and submission of claims.
This press release contains forward-looking statements. The word "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include, but are not limited to those that refer to Cardiac Science's market leading position in the cardiac stress testing and diagnostic cardiology, the extension of that leadership through the introduction of new products, the relative importance of one or more particular products to Cardiac Science's business or any portion of its business, and the anticipated future introduction of new technologies and products. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
For more information,
Cardiac Science Corporation
Senior Vice President and CFO
Allen & Caron
EVC Group Inc.
SOURCE Cardiac Science Corporation